GlassScriptPhysician profile
Cynthia Rodriguez
NPI 1124282553
$5,070.81
in general payments reported to CMS, 2019-2025
23 companies · $777 in 2025
The $777 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $562 · 2022: $653 · 2023: $1,397 · 2024: $1,681 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,855.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,168.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $583.16 | 2022-2025 | Lokelma, Farxiga |
| Lilly USA, LLC | $508.59 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Medtronic, INC. | $436.66 | 2021-2023 | Interstim |
| Inspire Medical Systems, INC. | $332.35 | 2023-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $265.08 | 2023-2024 | |
| Abbvie INC. | $227.05 | 2024 | |
| Dexcom, INC. | $218.93 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Amgen INC. | $210.62 | 2024-2025 | Evenity, Krystexxa, Otezla |
| Astellas Pharma US INC | $203.75 | 2023-2024 | Veozah |
| Intuity Medical INC | $148.90 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Biomarin Pharmaceutical INC. | $133.93 | 2025 | Voxzogo 1.2mg |
| Averitas Pharma INC. | $132.45 | 2024 | Qutenza |
| Gilead Sciences, INC. | $100.63 | 2024 | Epclusa |
| Horizon Therapeutics Plc | $91.73 | 2023 | Krystexxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.80 | 2023 | |
| Genentech USA, INC. | $61.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $44.32 | 2022-2023 | |
| Nevro Corp. | $40.09 | 2024 | Senza |
| Ironwood Pharmaceuticals, INC | $24.26 | 2023 | Linzess |
| Kowa Pharmaceuticals America, INC. | $19.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.65 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $18.03 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.